TrialSignal transduction and targeted therapy2026

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.

Yu-Tao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.